Канал: MYELOMA360

$Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma$

Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma

MYELOMA360

MYELOMA360

Expert Recommendations & Patient Perspectives for Treating Relapsed/Refractory Multiple Myeloma

Dr Sagar Lonial Discusses Data from ASCO and EHA 2019 in Transplant eligible patients

Dr Sagar Lonial discusses new data presented at ASCO and EHA 2019 on Cellular Therapies

Dr Sagar Lonial discusses new data from ASCO and EHA 2019 in Relapsed Refractory Myeloma

Dr Xavier Leleu discusses new data from ASCO & EHA 2019 in Transplant eligible Patients

Xavier Leleu discusses new data from ASCO and EHA 2019 in patients with myeloma who are not transpla

Dr Xavier Leleu discusses new data from ASCO and EHA 2019 on new agents in myeloma

Dr Xavier Leleu discusses new data from ASCO and EHA 2019 in refractory myeloma

Dr Sagar Lonial discusses new data from ASCO and EHA 2019 in the Transplant & Induction setting

Dr Xavier Leleu discusses the Forte trial ASCO 2019 Abstract 8002

Xavier Leleu Part 1 CASSIOPEIA

Richard LeBlanc ASH Abstract 4666

Dr Sagar Lonial discusses new data presented at ASCO and EHA 2019 in Smoldering Myeloma

Kristen Sanfilippo, MD Discusses ASH 2018 Abstract 141

Mark Bustoros, MD discusses ASH 2018 Abstract 804

Ehsan Malek Discusses ASH 2018 Abstract 1962

Saad Usmani, MD Discusses ASH 2018 Abstract 3288

David Siegel, MD, PhD discusses ASH 2018 Abstract 3271

David Siegel, MD PhD Discusses Myeloma Highlights from ASH 2018

Michael Kauffman, MD, PhD Discusses Selinexor Data Presented at ASH 2018

Marc Baertsch discusses ASH 2018 Abstracts 253 & 254

Sara Bringhen, MD Abstract 1990

Binod Dhakal ASH 2018 Abstract 1998

Hiroyuki Takamatsu ASH 2018 Abstract 258

Treatment and Survival of Patients with Primary Plasma Cell Leukemia

EHA 2018 Abstract PS1293

EHA 2018 Abstract PF560

EHA 2018: Abstract S109

Dr. Paul Richardson: EHA 2018 Abstract S847

Dr. Karim Iskander discusses EHA 2018 abstract S849

Francesca Gay Discusses ASH 2017 Abstract 4541

Novel Administration of Daratumumab

Minimal Residual Disease (MRD) in Multiple Myeloma (Full Interview)

Key Themes in Multiple Myeloma from the ASH 2017 Meeting

What Level of MRD Detection is Necessary to Infer Improved Survival?

When is Achieving MRD Negativity Most Important?

The Future of MRD Testing

How Might MRD Testing Affect Treatment Decisions?

MRD Testing Using NGS vs. Flow Advantages & Disadvantages

The Importance of MRD

Expert Panel: New Data in Newly Diagnosed Multiple Myeloma

Expert Panel: New Data in Relapsed Refractory Multiple Myeloma

New Data in Smoldering Myeloma (Expert Panel Discussion)

ASH 2017 Abstracts 501 and 504: Highlights of TeneoBio's technology

ASH 2017 Abstracts 436, 1854, 3040: Highlights from the Myeloma XI Study

ASH 2017 Abstract 1871: Impact of Pneumococcal Vaccination on Multiple Myeloma

Expert Panel Discusses CAR T-Cell Therapy in Multiple Myeloma

Real World Data in Multiple Myeloma: ASH 2017 Abstracts 3463 and 2171

Expert Panel Discussion on the use of Novel Therapies in Multiple Myeloma

CAR-T Cells in Multiple Myeloma

Rafael Fonseca discusses MOA and Its Impact on Myeloma Treatment